Co-Authors
This is a "connection" page, showing publications co-authored by DANIEL D KARP and DAVID VINING.
Connection Strength
0.200
-
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology. NPJ Precis Oncol. 2022 Oct 27; 6(1):78.
Score: 0.056
-
Ipilimumab, Pembrolizumab, or Nivolumab in Combination with BBI608 in Patients with Advanced Cancers Treated at MD Anderson Cancer Center. Cancers (Basel). 2022 Mar 04; 14(5).
Score: 0.053
-
Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. NPJ Precis Oncol. 2021 Mar 19; 5(1):21.
Score: 0.050
-
A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement. Cancer Chemother Pharmacol. 2018 11; 82(5):877-885.
Score: 0.042